1336 Federal Register / Vol. 62, No. 6 / Thursday, January 9, 1997 / Notices

small business when there is a

reasonable expectation of obtaining

competition from two or more small

businesses. If no expectation exists, the

procurements will be conducted on an

unrestricted basis.

Region 2 encompasses the states of

New Jersey, New York, and territories of

Puerto Rico and the Virgin Islands.

Region 3 encompasses the states of

Pennsylvania, Delaware, West Virginia,

Maryland (except Montgomery and

Prince Georges Counties), and Virginia

(except the city of Alexandria and the

counties of Arlington, Fairfax, Loudoun,

and Prince William).

Region 5 encompasses the states of

Illinois, Indiana, Ohio, Michigan,

Minnesota, and Wisconsin.

Region 6 encompasses the states of

Iowa, Kansas, Missouri and Nebraska.

Region 7 encompasses the states of

Arkansas, Louisiana, Oklahoma, New

Mexico, and Texas.

Region 8 encompasses the states of

Colorado, Montana, North Dakota,

South Dakota, Utah, and Wyoming.

Region 9 encompasses the states of

Arizona, California, Hawaii, and

Nevada.

The National Capital Region

encompasses the District of Columbia,

Montgomery and Prince Georges

counties in Maryland, and the city of

Alexandria and the counties of

Arlington, Fairfax, Loudoun, and Prince

William in Virginia.

Trash/garbage Collection Services in

PSC S205

Procurements for trash/garbage

collection services in PSC S205 will be

conducted on an unrestricted basis.

Architect-Engineer Services (All PSC

Codes Under the Demonstration

Program)

Procurements for all architectengineer services (except procurements

issued by contracting activities in GSA

Regions 4, 5, 9, and the National Capital

Region) shall be conducted on an

unrestricted basis.

Procurements for architect-engineer

services issued by contracting activities

in Regions 4, 5, 9, and the National

Capital Region shall be set aside for

small business when there is a

reasonable expectation of obtaining

competition from two or more small

businesses. If no expectation exists, the

procurements may be conducted on an

unrestricted bases.

Region 4 encompasses the states of

Alabama, Florida, Georgia, Kentucky,

North Carolina, South Carolina,

Mississippi, and Tennessee.

Region 5 encompasses the states of

Illinois, Indiana, Ohio, Michigan,

Minnesota, and Wisconsin.

Region 9 encompasses the states of

Arizona, California, Hawaii, and

Nevada.

The National Capital Region

encompasses the District of Columbia,

Montgomery and Prince Georges

counties in Maryland, and the city of

Alexandria and the counties of

Arlington, Fairfax, Loudoun, and Prince

William in Virginia.

Non-Nuclear Ship Repair

GSA does not procure non-nuclear

ship repairs.

Dated: December 16, 1996.

Ida M. Ustad,

Deputy Associate Administrator for

Acquisition Policy.

[FR Doc. 97–526 Filed 1–8–97; 8:45 am]

BILLING CODE 6820–61–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Committee on Vital and Health

Statistics: Meetings

Pursuant to the Federal Advisory

Committee Act, the Department of

Health and Human Services announces

the following advisory committee

meetings.

Name: National Committee on Vital and

Health Statistics (NCVHS), Subcommittee on

Health Data Needs, Standards, and Security.

Times and Dates:

9:00 a.m.–5:30 p.m., January 21, 1997.

9:00 a.m.–5:30 p.m., January 22, 1997.

9:00 a.m.–5:30 p.m., February 10, 1997.

9:00 a.m.–5:30 p.m., February 11, 1997.

Place: Room 503A, Hubert H. Humphrey

Building, 200 Independence Avenue, SW.,

Washington, D.C. 20201.

Status: Open.

Purpose: Under the Administrative

Simplification subtitle of the Health

Insurance Portability and Accountability Act

of 1996 (Pub. L. No. 104–191), the Secretary

of Health and Human Services is required to

adopt standards for specified transactions to

enable health information to be exchanged

electronically. The law requires that, within

24 months of adoption, all health plans,

health care clearinghouses, and health care

providers who choose to conduct these

transactions electronically must comply with

these standards. The Secretary is required to

consult the NCVHS in complying with these

provisions. As part of the consultation

process, the Committee will submit

recommendations to the Secretary during

1997.

To assist in the development of the NCVHS

recommendations to HHS, the NCVHS

Subcommittee on Health Data Needs,

Standards, and Security is holding a series of

public meetings to obtain the views,

perspectives and concerns of interested and

affected parties. The Subcommittee

recognizes that there are natural tensions

which exist between those who generate the

information which goes into these

transactions and those who use the

information. At the meetings, the

Subcommittee will discuss these and other

issues which may arise when a uniform set

of standards must be implemented by all data

generators and users. Generators of this data

include hospitals, physicians, nurses,

dentists, pharmacists, and other providers of

health care. Users of this data include health

insurers, health plans, researchers, and

managers of quality, utilization and risk.

For the meetings, specific organizations

representing both the generators and users of

this data will be invited by the Subcommittee

to provide answers to the following questions

in writing, to make brief oral presentations of

their answers, and to answer further

questions from the Subcommittee.

Representatives of ANSI accredited

Standards Developing Organizations will be

asked to present their views of these issues

as well.

Questions To Be Addressed

1. What are your organization’s

expectations for the results of the

Administrative Simplification standards

requirements in the Health Insurance

Portability and Accountability Act of 1996

(HIPAA)? In what ways will the outcome

affect the members of your organization, both

positively and negatively?

2. Does your organization have any

concerns about the process being undertaken

by the Department of Health and Human

Services to carry out the Administrative

Simplification requirements of this law? If so,

what are those concerns and what

suggestions do you have for improvements?

3. What major problems are experienced by

the members of your organization with the

current transactions specified under the

HIPAA? For generators of the data, how

readily available is the information that you

need to provide for the transactions and how

meaningful is that information from a clinical

perspective? For users of the data, are you

receiving the information you need from the

transactions to pay the bill, manage the care

process, etc., and what is your perception of

its quality?

4. How can the goal of administrative

simplification best be achieved while

meeting the business needs of all

stakeholders?

In addition, the Subcommittee will receive

a presentation from the Health Care

Financing Administration on unique

identifiers for providers and payers on

January 21. On January 22, the Subcommittee

will discuss other business consistent with

its charge.

Notice: In the interest of security, the

Department has instituted stringent

procedures for entrance to the Hubert H.

Humphrey building by non-government

employees. Thus, persons without a

government identification card should plan

to arrive at the building each day either

between 8:30 and 9:00 a.m. or 12:30 and 1:00

p.m. so they can be escorted to the meeting.

Entrance to the meeting at other times during

the day cannot be assured.

FOR FURTHER INFORMATION

CONTACT: Substantive program information
Federal Register / Vol. 62, No. 6 / Thursday, January 9, 1997 / Notices 1337

as well as summaries of the meeting and a

roster of committee members may be

obtained from James Scanlon, NCVHS

Executive Staff Director, Office of the

Assistant Secretary for Planning and

Evaluation, DHHS, Room 444–D. Humphrey

Building, 200 Independence Avenue S.W.,

Washington, D.C. 20201, telephone (202)

690–7100, or Marjorie S. Greenberg, Acting

Executive Secretary, NCVHS, NCHS, CDC,

Room 1100, Presidential Building, 6525

Belcrest Road, Hyattsville, Maryland 20782,

telephone (301) 436–7050. Information also

is available on the NCVHS homepage: http:/

/aspe.os.dhhs.gov/ncvhs/index.htm.

Dated: January 2, 1997.

James Scanlon,

Director, Division of Data Policy, Office of

the Assistant Secretary for Planning and

Evaluation.

[FR Doc. 97–434 Filed 1–8–97; 8:45 am]

BILLING CODE 4151–04–M

Centers for Disease Control and

Prevention

Epidemiology Program Office, Office of

the Director, Centers for Disease

Control and Prevention (CDC), Notice

of Meeting

Name: Guide to Community Preventive

Services Task Force Meeting.

Times and Dates: 8:30 a.m.–5 p.m., January

27, 1997; 8:30 a.m.–5 p.m., January 28, 1997.

Place: Terrace Garden Inn, 3405 Lenox

Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by

the space available.

Purpose: The mission of the Task Force is

to develop and publish a Guide to

Community Preventive Services, which is

based on the best available scientific

evidence and current expertise regarding

essential public health services and what

works in the delivery of those services. The

primary purpose of this second meeting is to

continue in the development of a shared

vision for the Guide; review and assess the

methods used in the initial development of

the first two chapters; and to select

additional topics to be included in the Guide.

Matters to be Discussed: Agenda items

include the definition of ‘‘community’’ for

the Guide; defining target audiences of the

Guide; process for selection of topics to be

included in the Guide; updates on current

chapters in progress: the prevention of (a)

motor vehicle injuries and (b) vaccine

preventable diseases; and selection of new

topics for upcoming chapters.

Agenda items are subject to change as

priorities dictate.

FOR ADDITIONAL INFORMATION

CONTACT: Marguerite Pappaioanou, Chief,

Community Preventive Service Guide

Development Activity, Division of Prevention

Research and Analytic Methods,

Epidemiology Program Office, CDC, 1600

Clifton Road, NE, M/S D–01, Atlanta, Georgia

30333, telephone 404/639–4301.

Persons wishing to reserve a space for this

meeting should call 404/639–4311 by close of

business on January 21, 1997.

Dated: January 3, 1997.

Joseph E. Salter

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–467 Filed 1–8–97; 8:45 am]

BILLING CODE 4163–18–P

National Center for Environmental

Health (NCEH) of the Centers for

Disease Control and Prevention (CDC);

Notice of Meeting

Name: Translating Advances in Genetics

into Public Health Action.

Times and Dates: 10 a.m.–5:30 p.m.,

January 27, 1997; 8 a.m.–3 p.m., January 28,

1997.

Place: Terrace Garden Hotel, 3405 Lenox

Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by

the space available.

Purpose: CDC has established a Task Force

on Genetics in Disease Prevention to: (1)

develop a strategic plan for CDC-wide

genetics programs, (2) coordinate and

support program efforts, and (3) convene

constituents and consultants for their

individual advice on strategic planning,

priorities for CDC activities, and policy

development. This Task Force was formed in

October, and is in the process of collecting

and summarizing information about CDC

efforts related to genetics that will be used

during strategic planning.

This meeting will enable invited

participants (individuals from academia,

public health, professional organizations,

consumer groups, and industry) to provide

input and discuss strategic planning issues

and needs associated with the translation of

advances in genetics into public health

action. Information gained from this meeting

will be considered, along with that

previously received, in drafting strategic

planning documents. These documents will

then be distributed for further comment.

Matters to be Discussed: Agenda items

include discussions on population-based

assessment functions, development of public

health policies and guidelines, quality

assurance and prevention effectiveness

functions, and needs for professional

education and information dissemination

efforts.

Agenda items are subject to change as

priorities dictate.

FOR FURTHER INFORMATION

CONTACT: Dometa Williams, Genetics Task

Force, NCEH, CDC, 4770 Buford Highway,

NE, Atlanta, Georgia 30341, telephone 770/

488–7120, FAX 770/488–7197.

Dated: January 3, 1997.

Joseph E. Salter,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–460 Filed 1–8–97; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 97N–0003]

Hoffman-LaRoche, Inc., et al.;

Withdrawal of Approval of 11 New

Drug Applications, 1 Abbreviated

Antibiotic Application, and 20

Abbreviated New Drug Applications

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is withdrawing

approval of 11 new drug applications

(NDA’s), 1 abbreviated antibiotic

application (AADA), and 20 abbreviated

new drug applications (ANDA’s). The

holders of the applications notified the

agency in writing that the drug products

were no longer marketed and requested

that the approval of the applications be

withdrawn.

EFFECTIVE DATE: February 10, 1997.

FOR FURTHER INFORMATION CONTACT:

Olivia A. Vieira, Center for Drug

Evaluation and Research (HFD–7), Food

and Drug Administration, 7500 Standish

Pl., Rockville, MD 20855, 301–594–

1046.

SUPPLEMENTARY INFORMATION: The

holders of the applications listed in the

table in this document have informed

FDA that these drug products are no

longer marketed and have requested that

FDA withdraw approval of the

applications. The applicants have also,

by their request, waived their

opportunity for a hearing.

Application no. Drug Applicant

NDA 6–525 ................. Gantrisin (sulfisoxazole) Tablets ......................................... Hoffman-La Roche, Inc., 340 Kingsland St., Bldg. 719–4,

Nutley, NJ 07110.

NDA 12–486 ............... Taractan (chlorprothixene) Tablets ...................................... Do.

NDA 12–772 ............... Haldrone (paramethasone acetate) Tablets ........................ Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN

46285.